Zenflow Secures $52M Financing and Partners with Cook Medical

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 /CourierPR/ -- Zenflow, a company developing innovative therapies for benign prostatic hyperplasia (BPH), has secured an oversubscribed $52 million Series D financing round. The round was led by Cook Medical, with participation from new investor ClavystBio, and existing investors Invus Opportunities, F-Prime, Medtech Venture Partners, and others. The financing was further supported by venture debt financing from HSBC Bank USA, N.A. and Trinity Capital. The proceeds will accelerate the company’s commercial launch following the U.S. Food and Drug Administration’s (FDA) PMA approval of the Zenflow Spring® System, which was achieved in December 2025.

The Zenflow Spring System is the first and only product to offer simple, in-office treatment for BPH, with sizing options and full reversibility if desired. For the more than 30 million U.S. men living with BPH, the Spring treatment opens a new category of treatment called first-line interventional therapy (FIT), giving physicians a device-based option they can offer instead of drug therapy. The long-term durability and safety advantages of the Spring treatment include no post-procedure catheter and preservation of sexual function.

In addition to the financing, Zenflow announced it has entered into an exclusive U.S. distribution agreement with Cook Medical, a leading medical device company with a proven track record in urology.

The distribution agreement brings together Zenflow's operational and clinical expertise and Cook Medical's established commercial presence in urology, creating a powerful partnership that expands patient access to this novel BPH therapy.

According to the Global Burden of Disease Study 2019, an estimated 32 million men over the age of 60 in the United States and 79 million men worldwide live with BPH.1 More than 50% of men are impacted by BPH symptoms by age 50, 70% of men by age 70, and 90% of men by age 80.2

1. Ye, Z., Wang, J., Xiao, Y. et al. Global burden of benign prostatic hyperplasia in males aged 60-90 years from 1990 to 2019: results from the global burden of disease study 2019. BMC Urol 24, 193 (2024). doi.org/10.1186/s12894-024-01582-w link.springer.com/article/10.1186/s12894-024-01582-w#citeas 2. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9(Suppl 9):S3-S14. PMID: 16985902; PMCID: PMC1477638. pmc.ncbi.nlm.nih.